ESTRO 2022 - Abstract Book

S317

Abstract book

ESTRO 2022

Conclusion We determined 3 risk classes for RT-induced acute side effects based on the combination of MB information and cytokine profile. The biologically personalised risk prediction improves discrimination and allows to the design of possible interventional trials to reduce tox by modifying MB/inflammation levels before RT starts.

MO-0382 Learning from every patient‘s biomarker - Stem cells, hypoxia, HPV and tumor volume in Dahanca 5

J. Overgaard 1 , B. Singers Sørensen 1 , K. Toustrup 1 , P. Lassen 1 , J. Alsner 1

1 Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus N, Denmark

Purpose or Objective Background and purpose: Tumor control after radiotherapy (RT) is based on eradication of all clonogenic stem cells. Not all tumor cells possess the clonogenic potential, but genetic biomarkers associated with stem cell density has been identified. These may be linked with tumor hypoxia, a known cause of radioresistance. Both stem cells and hypoxia are associated with tumor volume. HPV/p16 found to influence the outcome of head and neck squamous cell carcinoma (HNSCC). We aim to evaluate the impact of gene expression markers of tumor stem cells, hypoxia and HPV in an attempt to identify patients with HNSCC having benefit of RT with or without hypoxic modification with nimorazole. Materials and Methods Patients and methods: Gene expressions for stem cells (CMET, SLC3A2), hypoxia (15-gene profile), and HPV (p16) were quantified from formalin-fixed, paraffin-embedded tumor biopsies of 270 HNSCC patients randomized to receive placebo or nimorazole in conjunction with RT. (Radiother Oncol 102:122-9, 2012). Stem cell markers (CMET and SLC3A2) were used to define a stem cell profile based on tertiles of expression. This was combined with the expression of the hypoxic gene profile in patients not given nimorazole, and taking the p16 expression into consideration. Outcome was evaluated in terms of loco-regional tumor control (LRC) and disease-specific survival (DSS).